OCTO-TELEMATICS
19.7.2021 09:02:15 CEST | Business Wire | Press release
OCTO Telematics, the leading insurance and fleet telematics services and analytics provider, today announced plans to hire more than 100 people as part of its ‘Smart Data, Smarter People’ program.
“Investment in top talent is indicative of the importance we place on continuous innovation to help organizations thrive by leveraging data and analytics to address fast-changing consumer needs”, said Paolo Codazzi, Group Chief HR & Organisation Officer, OCTO Telematics. “We are focused on developing our team with top talent from diverse cultural backgrounds that will not only be well versed in current and emerging technologies, but also in designing the mobility of the future.”
If the recruitment of ICT profiles mainly concerns the Rome office, the inclusion of commercial figures and those dedicated to business development concern other markets in which OCTO is growing, such as the United States and Europe. In addition to selected recent successful hirings in the United States, France, Switzerland, Spain and, last but not least, Italy we are pleased to announce that the OCTO’s Team in the UK is strengthened by the addition of 4 key leaders.
Vernon Bonser, joint OCTO Telematics as UK Commercial VP, after 21 years spent in the Fleet and Video Telematics market working, among others, for Cybit / Masternaut, Webfleet (formerly TomTom Telematics) and VisionTrack. Travis Kenny, as Sales Manager UK, joining with a strong background that includes Vision Track, Ryder System Inc and Tantalum Innovations.
Finally, two Global Stream Leaders, will be based out of the UK: Andy Walters as Global Stream Leader Fleet & Trucks and Henry Peacock as Global Stream Leader Industrial. The combined skillset and experience of these four leaders is the evidence of OCTO’s ambitious growth strategy.
Connected vehicle services amounted to US$400 billion in 2018 and may reach US$1 million by 2025. Between 2019 and 2030 the number of self-driving vehicles sold each year globally will increase from 50,000 to more than 18 million, revolutionising car use and the entire concept of mobility. OCTO’s ‘Smart Data, Smart People’ program will strengthen the company's technological and market leadership in connected services and solutions with an infusion of advanced technical skills in big data, data science, analytics and telematics. The talent will also bolster the company’s commitment to capabilities that advance OCTO’s Vision Zero (zero accidents, zero congestion, zero pollution) efforts globally.
About OCTO Telematics
Founded in 2002, OCTO is a leading provider of telematic services and advanced data analytics for the Insurance sector, and increasingly one of the leading companies offering solutions for Fleet Telematics and Smart Mobility. With OCTO’s unique propositions already established in the field of Insurtech and Smart Mobility, OCTO continues to expand in new sectors and international markets. In the context of an increasingly connected world, OCTO’s advanced analytics and its set of IoT Big Data generate actionable analytics, giving life to a new era of Smart Telematics. Today it has over 5.5 million connected users and the largest database of vehicle telematics data in the world, with over 290 billion miles of driving data collected and 485.000 claims and insurance events analyzed. It also manages over 400.000 vehicle rentals per month.
For more information, go to www.octotelematics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005038/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom